Compare CBL & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBL | NVCR |
|---|---|---|
| Founded | 1978 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1995 | 2015 |
| Metric | CBL | NVCR |
|---|---|---|
| Price | $42.28 | $12.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $45.00 | $28.08 |
| AVG Volume (30 Days) | 170.9K | ★ 1.0M |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.25% | N/A |
| EPS Growth | ★ 132.09 | 21.79 |
| EPS | ★ 4.34 | N/A |
| Revenue | $578,373,000.00 | ★ $655,353,000.00 |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | N/A | $6.74 |
| P/E Ratio | $9.76 | ★ N/A |
| Revenue Growth | ★ 12.18 | 8.28 |
| 52 Week Low | $22.73 | $9.82 |
| 52 Week High | $43.21 | $20.05 |
| Indicator | CBL | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 68.63 | 57.94 |
| Support Level | $36.41 | $10.72 |
| Resistance Level | N/A | $13.78 |
| Average True Range (ATR) | 1.09 | 0.59 |
| MACD | 0.29 | 0.13 |
| Stochastic Oscillator | 83.93 | 91.54 |
CBL & Associates Properties Inc is a real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.